DOI: 10.1055/s-00000069

Seminars in Liver Disease

References


Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes).
Accessed June 15, 2021 at:
https://ClinicalTrials.gov/show/NCT02993406

Download Bibliographical Data

Search in: